CSBR (Champions Oncology) Cash per Share: $0.35 (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CSBR Champions Oncology Inc CSBR
53 GF Score
Price $5.18
GF Value $6.68
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Champions Oncology Cash per Share?

Champions Oncology CSBR -0.19% 53 Cash per Share is $0.35 as of Apr. 2026. GuruFocus rates CSBR with a GF Score™ of 53/100 and a GF Value™ of $6.68 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Champions Oncology's Cash per Share for the quarter that ended in Apr. 2026 was $0.35.

Champions Oncology  (NAS:CSBR) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Champions Oncology Cash per Share Related Terms

Champions Oncology Cash per Share Historical Data

* Premium members only.

The historical data trend for Champions Oncology's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Champions Oncology Cash per Share Chart

Champions Oncology Annual Data
Trend Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25 Apr26
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.67 0.75 0.19 0.71 0.35

Champions Oncology Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.71 0.75 0.61 0.51 0.35
CSBR
53GF Score
Champions Oncology Inc CSBR
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Champions Oncology Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Champions Oncology's Cash per Share for the fiscal year that ended in Apr. 2026 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=4.872/13.89
=0.35

Champions Oncology's Cash per Share for the quarter that ended in Apr. 2026 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=4.872/13.89
=0.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of $0.35 mean?
Champions Oncology (CSBR) has a Cash per Share of $0.35 as of Apr. 2026. Cash per share is the per-share value of a company's available cash. View historical data for Champions Oncology and its competitors.
Is Champions Oncology's Cash per Share too high?
Champions Oncology's current Cash per Share is $0.35. Overall, Champions Oncology has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's Cash per Share compare to RLYB and NRXS?
Champions Oncology's Cash per Share of $0.35 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Biotechnology company?
A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Champions Oncology and its competitors. Champions Oncology's current Cash per Share is $0.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.68, compared to a current price of $5.18 — trading 22.5% below its estimated fair value. The current Cash per Share is $0.35. Champions Oncology's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Champions Oncology (CSBR), the current Cash per Share is $0.35 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Champions Oncology (CSBR) Overvalued in 2026?

Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued. The current stock price of $5.18 is trading 22.5% below its estimated GF Value™ of $6.68. GuruFocus considers Champions Oncology to be Modestly Undervalued.

Key valuation signals for CSBR:

  • Cash per Share: $0.35
  • GF Value™: $6.68 vs. price of $5.18 (22.5% below fair value)
  • GF Score™: 53/100 with 3 warning signs

No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Champions Oncology Business Description

Address One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
53GF Score

Get the complete analysis for CSBR

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.18
Price
$6.68
GF Value